Exclusive: Big hedge funds call on doctors, scientists for an edge on pharma Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol-Myers Squibb stock has rebounded strongly ... When BMY completed its deal for Celgene in 2020, it inherited several multi-billion dollar selling drug products, such as >$12bn per annum ...
Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups. With 78% stake, institutions possess the maximum shares in the company.
Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised ... the then-pipeline asset despite its pending acquisition of Celgene. Based on that decision, Celgene sold its mega-blockbuster ...
1 Day BMY 0.84% DJIA -0.16% S&P 500 -0.21% Health Care/Life Sciences 0.69% ...
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's (BMY.N), opens new tab blockbuster cancer drug, Opdivo. Opdivo is part of ...
A big dividend yield for a few years doesn't mean much if it can't be sustained. Even though Bristol-Myers Squibb isn't generating a profit, it is generating healthy free cash flows that easily ...
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price target of $70.00. The company’s shares opened ...
Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 10 unusual trades. Delving into the details ...
The FDA has reportedly approved an injectable formulation of Bristol-Myers Squibb's (NYSE:BMY) oncology drug Opdivo. Previously, the PD-1 inhibitor drug was only available through IV infusion.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...